Extrarenal Manifestations in Shigatoxin-associated Haemolytic Uremic Syndrome

J. Matthies; C. Hünseler; R. Ehren; R. Volland; F. Körber; B. Hoppe; L. T. Weber; S. Habbig

doi:10.1055/s-0042-108444

Klinische Pädiatrie, Inhaltsverzeichnis

Klin Padiatr 2016; 228(04): 181-188
DOI: 10.1055/s-0042-108444

Original Article

Extrarenal Manifestations in Shigatoxin-associated Haemolytic Uremic Syndrome

Extrarenale Manifestationen bei Shigatoxin-Assoziiertem Hämolytisch-Urämischen Syndrom

Authors

J. Matthies

¹Division of Pediatric Nephrology, University Children’s and Adolescent’s Hospital, University Hospital of Cologne, Germany
C. Hünseler

²Division of Pediatric Gastroenterology, University Children’s and Adolescent’s Hospital of Cologne, Germany
R. Ehren

¹Division of Pediatric Nephrology, University Children’s and Adolescent’s Hospital, University Hospital of Cologne, Germany
R. Volland

³Pediatric Study Center, University Children’s Hospital of Cologne, Germany
F. Körber

⁴Division of Pediatric Radiology, Department of Radiology, University Hospital of Cologne, Germany
B. Hoppe

⁵Division of Pediatric Nephrology, University Children’s Hospital Bonn, Germany
L. T. Weber

¹Division of Pediatric Nephrology, University Children’s and Adolescent’s Hospital, University Hospital of Cologne, Germany
S. Habbig

¹Division of Pediatric Nephrology, University Children’s and Adolescent’s Hospital, University Hospital of Cologne, Germany

Abstract

Background: Shigatoxin-associated haemolytic uremic syndrome (STEC-HUS) is the most frequent cause of acute kidney injury in children worldwide. Extrarenal manifestations are the main determinants for both, short- and long-term prognosis of patients with STEC-HUS.

Patients: 46 patients treated over the last 10 years for STEC-HUS in a single center.

Methods: This retrospective study analysed the incidence and outcome of extrarenal manifestations in our cohort of children with STEC-HUS. Risk factors for extrarenal involvement and adverse outcome were assessed by detailed chart review.

Results: Eleven extrarenal manifestations occurred in 9/46 patients comprising 8 neurological, 2 gastro-intestinal, and 1 cardiovascular complication. One patient died from cerebral bleeding. Liver transplantation was required in a girl 18 months after HUS due to secondary sclerosing cholangitis. Patients with extrarenal manifestations were significantly younger and presented with higher leucocyte counts and higher alanine aminotransferase levels at admission. Renal replacement therapy was necessary for a longer period than in patients without extrarenal complications.

Conclusion: Extrarenal manifestations occurred in about 20% of our patients with STEC-HUS. The identification of risk-factors will help to provide a better management of these patients which might also include novel treatment strategies like complement inhibition.

Zusammenfassung

Hintergrund: Shigatoxin-assoziiertes hämolytisch-urämisches Syndrom (STEC-HUS) ist der häufigste Grund für ein akutes Nierenversagen bei Kindern weltweit. Extrarenale Manifestationen haben einen bedeutenden Einfluss sowohl für die kurz- als auch langfristige Prognose der Patienten.

Patienten: 46 Patienten mit STEC-HUS, die in den letzten 10 Jahre in unserem Zentrum behandelt wurden.

Methoden: Diese retrospektive Studie analysiert die Inzidenz und die Folgen von extrarenalen Komplikationen bei STEC-HUS. Zudem werden mögliche Risikofaktoren für eine extrarenale Beteiligung untersucht.

Ergebnisse: Elf extrarenale Manifestationen sind bei insgesamt 9/46 Patienten aufgetreten: 8 neurologische, 2 gastroenterologische und 1 kardiovaskuläre Komplikation. Ein Patient verstarb an einer Gehirnblutung. Eine Patientin erhielt eine Lebertransplantation 18 Monate nach STEC-HUS aufgrund einer sekundär sklerosierenden Cholangitis. Patienten mit extrarenalen Manifestationen waren signifikant jünger und hatten bei ihrer Aufnahme höhere Leukozyten- und Alanin-Aminotransferase-Werte. Ebenso war die Dialysetherapie über einen längeren Zeitraum notwendig.

Schlussfolgerung: Extrarenale Manifestationen traten bei 20% der Patienten auf. Die Identifikation von Risikofaktoren ermöglicht eine bessere Behandlung dieser Patienten, welche möglicherweise den Einsatz neuer Therapiemöglichkeiten wie Komplementinhibierung beinhalten.

Keywords

Children - Escherichia coli - Thrombotic Microangiopathy - Dialysis - Eculizumab

Schlüsselwörter

Kinder - Escherichia coli - Thrombotische Mikroangiopathie - Dialyse - Eculizumab

Volltext

Referenzen

References
1 Bauer A, Loos S, Wehrmann C et al. Neurological involvement in children with E. coli O104:H4-induced hemolytic uremic syndrome. Pediatr Nephrol 2014; 29: 1607-1615
2 Buteau C, Proulx F, Chaibou M et al. Leukocytosis in children with Escherichia coli O157:H7 enteritis developing the hemolytic-uremic syndrome. Pediatr Infect Dis J 2000; 19: 642-647
3 Eckart P, Guillot M, Jokic M et al. Cardiac involvement during classic hemolytic uremic syndrome. Arch Pediatr 1999; 6: 430-433
4 Elliott EJ, Robins-Browne RM, O’Loughlin EV et al. Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features. Arch Dis Child 2001; 85: 125-131
5 Frank C, Werber D, Cramer JP et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011; 365: 1771-1780
6 Gerber A, Karch H, Allerberger F et al. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997–2000, in Germany and Austria: a prospective study. J Infect Dis 2002; 186: 493-500
7 Gitiaux C, Krug P, Grevent D et al. Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab. Dev Med Child Neurol. 2013; 55: 758-765
8 Hanley JA, McNeil BJ.. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843
9 Hayes W, Tschumi S, Ling SC et al. Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol 2015; 30: 775-781
10 Hickey CA, Beattie TJ, Cowieson J et al. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 2011; 165: 884-889
11 Kamioka I, Yoshiya K, Satomura K et al. Risk factors for developing severe clinical course in HUS patients: a national survey in Japan. Pediatr Int 2008; 50: 441-446
12 Kielstein JT, Beutel G, Fleig S et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012; 27: 3807-3815
13 Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al. Eculizumab in Severe Shiga-Toxin–Associated HUS. N Engl J Med 2011; 364: 2561-2563
14 Loirat C, Fakhouri F, Ariceta G et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016; 31: 15-39
15 Loos S, Ahlenstiel T, Kranz B et al. An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 2012; 55: 753-759
16 Martin DL, MacDonald KL, White KE et al. The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota. N Engl J Med 1990; 323: 1161-1167
17 McCarthy DW, Mutabagani K, Mahan JD et al. Infarction of the choledochus, liver, gallbladder, and pancreas: a unique complication of the hemolytic uremic syndrome. J Pediatr Surg 2000; 35: 502-504
18 Michael M, Elliott EJ, Ridley GF et al. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev 2009; CD003595
19 Milford DV, Taylor CM, Guttridge B et al. Haemolytic uraemic syndromes in the British Isles 1985–8: association with verocytotoxin producing Escherichia coli. Part 1: Clinical and epidemiological aspects. Arch Dis Child 1990; 65: 716-721
20 Pape L, Hartmann H, Bange FC et al. Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement. Medicine (Baltimore) 2015; 94: e1000
21 Poulton J, Taylor CM, De Giovanni JV.. Dilated cardiomyopathy associated with haemolytic uraemic syndrome. Br Heart J 1987; 57: 181-183
22 Rosales A, Hofer J, Zimmerhackl L-B et al. Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis 2012; 54: 1413-1421
23 Tarr PI, Gordon CA, Chandler WL.. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365: 1073-1086
24 Thayu M, Chandler WL, Jelacic S et al. Cardiac ischemia during hemolytic uremic syndrome. Pediatr Nephrol 2003; 18: 286-289
25 Thomas NJ, Messina JJ, DeBruin WJ et al. Cardiac failure in hemolytic uremic syndrome and rescue with extracorporeal life support. Pediatr Cardiol 2005; 26: 104-106
26 Thurman JM, Marians R, Emlen W et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 1920-1924
27 Trachtman H, Austin C, Lewinski M et al. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 2012; 8: 658-669
28 Urushihara N, Ariki N, Oyama T et al. Secondary sclerosing cholangitis and portal hypertension after O157 enterocolitis: Extremely rare complications of hemolytic uremic syndrome. J Pediatr Surg 2001; 36: 1838-1840
29 Walters MD, Matthei IU, Kay R et al. The polymorphonuclear leucocyte count in childhood haemolytic uraemic syndrome. Pediatr Nephrol 1989; 3: 130-134